Epidemiology and Biometry Branch, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 5635 Fishers Lane, Rockville, MD, 20852, USA.
Mailman School of Public Health, Columbia University, 722 W. 168th Street, New York, New York, 10032, USA.
Drug Alcohol Depend. 2017 Dec 1;181:223-228. doi: 10.1016/j.drugalcdep.2017.09.032. Epub 2017 Oct 18.
To present information on predictors of treatment utilization and barriers to treatment utilization among individuals with lifetime DSM-5 cannabis use disorder (CUD).
Face-to-face survey of a representative sample of the adult US general population (n=36,309).
Treatment rates for CUD were low in this general population survey (13.7%). Severity of CUD and comorbidity of other lifetime drug use disorders were significant predictors of lifetime treatment utilization for CUD. Preference for self-reliance, minimizing problems, fear of stigma, and financial and structural issues were among the most frequently endorsed reasons for respondents not seeking treatment when they perceived the need for treatment among individuals with lifetime CUD, regardless of whether they eventually utilized treatment at some time in their lives.
Given the rising prevalence of CUD in the US over the past decade and currently low treatment rates for CUD, increased provision for services for CUD appears critically needed, especially those that screen for and treat, when present, other drug use disorders. Programs to reduce stigma and financial barriers are needed, as well as programs to increase awareness among the general public, health care professionals about the nature and seriousness of CUD, and the availability and effectiveness of treatment for this disorder.
介绍一生中患有 DSM-5 大麻使用障碍（CUD）的个体治疗利用的预测因素和治疗利用障碍的信息。
对美国成年总人口的代表性样本进行面对面调查（n=36309）。
在这项一般人群调查中，CUD 的治疗率较低（13.7%）。CUD 的严重程度和其他终生药物使用障碍的合并症是终生 CUD 治疗利用的显著预测因素。在一生中患有 CUD 的个体中，当他们认为需要治疗时，受访者最常表示不愿意寻求治疗的原因是自力更生的偏好、尽量减少问题、对污名的恐惧以及财务和结构问题，无论他们最终是否在一生中的某个时候接受了治疗。
鉴于过去十年美国 CUD 的患病率不断上升，而目前 CUD 的治疗率较低，因此似乎迫切需要增加 CUD 服务的提供，特别是那些对其他药物使用障碍进行筛查和治疗的服务。需要减少污名和经济障碍的计划，以及提高公众、医疗保健专业人员对 CUD 的性质和严重性以及治疗这种障碍的可用性和有效性的认识的计划。
